AU9664198A - Method for the treatment of cystic fibrosis - Google Patents

Method for the treatment of cystic fibrosis

Info

Publication number
AU9664198A
AU9664198A AU96641/98A AU9664198A AU9664198A AU 9664198 A AU9664198 A AU 9664198A AU 96641/98 A AU96641/98 A AU 96641/98A AU 9664198 A AU9664198 A AU 9664198A AU 9664198 A AU9664198 A AU 9664198A
Authority
AU
Australia
Prior art keywords
treatment
cystic fibrosis
cystic
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU96641/98A
Other languages
English (en)
Inventor
William Louis Macias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU9664198A publication Critical patent/AU9664198A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU96641/98A 1997-09-26 1998-09-23 Method for the treatment of cystic fibrosis Abandoned AU9664198A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6012897P 1997-09-26 1997-09-26
US60060128 1997-09-26
PCT/US1998/019906 WO1999016453A1 (en) 1997-09-26 1998-09-23 Method for the treatment of cystic fibrosis

Publications (1)

Publication Number Publication Date
AU9664198A true AU9664198A (en) 1999-04-23

Family

ID=22027540

Family Applications (1)

Application Number Title Priority Date Filing Date
AU96641/98A Abandoned AU9664198A (en) 1997-09-26 1998-09-23 Method for the treatment of cystic fibrosis

Country Status (5)

Country Link
EP (1) EP1007056A1 (de)
JP (1) JP2001517707A (de)
AU (1) AU9664198A (de)
CA (1) CA2304482A1 (de)
WO (1) WO1999016453A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
ID23219A (id) * 1998-04-17 2000-03-30 Lilly Co Eli Trisiklik tersubstitusi
US6576654B1 (en) * 1998-09-23 2003-06-10 Eli Lilly And Company Method for the treatment of cystic fibrosis
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
AU2001236440A1 (en) * 2000-01-25 2001-08-07 Eli Lilly And Company Method for the treatment of inflammation with spla2 inhibitors
JP2003527369A (ja) * 2000-03-13 2003-09-16 イーライ・リリー・アンド・カンパニー スルホンアミド誘導体
AU2001267823A1 (en) 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
EP1307461A2 (de) * 2000-08-04 2003-05-07 Eli Lilly And Company Substituierte pyrrol-verbindungen und ihre verwendung als spla2-hemmer
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
WO2006099256A2 (en) * 2005-03-11 2006-09-21 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2010027762A1 (en) * 2008-09-04 2010-03-11 Boehringer Ingelheim International Gmbh Indolizine inhibitors of leukotriene production
CN116472034A (zh) * 2020-06-12 2023-07-21 藤济(厦门)生物医药科技有限公司 茚化合物、其药物组合物及其治疗应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211783D0 (en) * 1992-06-04 1992-07-15 Ici Plc Amide derivatives
GB9214053D0 (en) * 1992-07-02 1992-08-12 Ici Plc Heterocyclic amides
US5436258A (en) * 1992-09-09 1995-07-25 Eli Lilly And Company Prevention of bone resorption
US5453443A (en) * 1994-07-20 1995-09-26 Merck Frosst Canada, Inc. Bis(aryloxy)alkanes as inhibitors of phospholipase A2 enzymes
GB9417956D0 (en) * 1994-09-02 1994-10-26 Merck Sharp & Dohme Therapeutic agents
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5618792A (en) * 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase

Also Published As

Publication number Publication date
JP2001517707A (ja) 2001-10-09
WO1999016453A1 (en) 1999-04-08
EP1007056A1 (de) 2000-06-14
CA2304482A1 (en) 1999-04-08

Similar Documents

Publication Publication Date Title
AU2420797A (en) Novel cystic fibrosis treatment
AU6578998A (en) Method of treatment of migraine
AU7169096A (en) Thrombosis treatment
AU7982498A (en) Water treatment process
AU2060097A (en) Massaging apparatus
AU9035498A (en) Method for treating pain
AU7600198A (en) Formation treatment method using deformable particles
AU6589798A (en) Ileus treatment method
AU7157896A (en) Cystic fibrosis therapy
AU3541595A (en) Method and composition for treating cystic fibrosis
AU9664198A (en) Method for the treatment of cystic fibrosis
AU1865497A (en) Method for the treatment of a liquid
AUPO900097A0 (en) Process
AU6185698A (en) Methods and compositions for treating cystic fibrosis
AU5339398A (en) Apparatus for cardiac treatment
AU6764798A (en) Leukotriene antagonists useful for treating cystic fibrosis
AU6883398A (en) Methods of treating bone loss
AU9034798A (en) Method for treating pain
AU2042097A (en) Treatment for pulmonary fibrosis
AU1926597A (en) Treatment of cocoa
AU4027097A (en) Method of treatment
AU1282099A (en) Method for treatment of disorders of attention
AU8860498A (en) Cleaning method
AU8031700A (en) Method of treating fibrosis
AU3817899A (en) Therapy of atherosclerosis

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase